FDA slaps new bladder cancer limits on Merck's Keytruda, Roche's Tecentriq

The FDA is continuing to review Merck's Keytruda and Roche's Tecentriq in previously untreated bladder cancer patients. (Merck)

Last month, the FDA warned that immuno-oncology stars from Merck and Roche might actually be hurting some previously untreated bladder cancer patients’ survival chances. And now, it’s followed up by narrowing the drugs’ labels.

The agency has restricted use of Merck’s Keytruda and Roche’s Tecentriq among patients with locally advanced or metastatic bladder cancer who aren’t eligible for cisplatin-containing chemo. Specifically, within that population, Keytruda is now OK’d only for patients whose tumors express levels of the biomarker PD-L1 that meet a combined positive score of 10 or higher. Tecentriq, meanwhile, can only be used for those whose PD-L1 immune cells cover 5% or more of their tumor area.

Patients who aren’t eligible for any platinum-containing therapy can still take either drug, regardless of their PD-L1 status, regulators said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The moves follow findings announced in May that in each of two studies—one testing Keytruda and the other testing Tecentriq—patients with low PD-L1 levels treated with the drugs saw their survival chances sink compared with those who took platinum chemotherapy.

RELATED: Merck's Keytruda, Roche's Tecentriq may lag chemo in some cancer patients, FDA says

The FDA’s review of the situation is ongoing, it said, and it will continue to communicate new information regarding the drugs as it rolls in. For now, though, it recommends that cisplatin-ineligible patients with low PD-L1 levels continue taking the drugs in question, as long as they’re responding to therapy.

RELATED: The gang's all here: Merck's Keytruda nabs I-O's third bladder cancer approval this month

The changes mark a setback for both Merck and Roche in an ultracompetitive area. Bladder cancer is the only field in which all five members of the PD-1/PD-L1 class—which also includes AstraZeneca’s Imfinzi, Bristol-Myers Squibb’s Opdivo and Merck KGaA and Pfizer’s Bavencio—boast approvals.

As the agency was quick to point out, though, it hasn’t changed the indications for Keytruda and Tecentriq patients who have seen their disease progress after other therapies, and patients taking the drugs for other approved uses “should continue to take their medication as directed by their health care professional,” it said.

Suggested Articles

Astellas and Amgen agreed to pay nearly $125 million to settle Justice Department allegations that they used charity contributions as kickbacks.

Bristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. Bristol’s execs? Not so…

China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.